Integrating the significance of prognosis, TIICs, ICP genes, and MSI and (or) TMB, we induced that HMGBs might be promising immunological targets for the following cancers: HMGB1 for ACC and KIRC; HMGB2 for ACC and LGG; and HMGB3 for BRAC, SARC, SKCM, and OV. This evidence concerns the gene HMGB1 and adrenal cortex carcinoma.